factor receptors (PDGFRs), vascular endothelial growth factor receptors (VEGFRs), stem cell factor receptor (c-Kit), colony stimulating factor 1 receptor (CSF-1R), and fms-related tyrosine kinase 3 (Flt-3) (1, 2, 9, 13, 19, 21, 32, 43) . It has been well established that sunitinib suppresses tumor angiogenesis mainly through VEGFR-2 (KDR/Flk-1), which is expressed on endothelial cells and is known to play a critical role in angiogenesis (9, 13, 19) . In addition, sunitinib is reported to have direct antiproliferative and/or apoptotic effects on tumor cells, which express target RTKs (22, 33, 39) .
It was previously shown that, unlike other representative RTKs, VEGFR-2 utilizes the phospholipase C (PLC)-␥/protein kinase C (PKC)/Raf/mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway as the major signaling pathway. In contrast, Ras is poorly activated in VEGFR-2-related signaling pathways (40, 41) .
Advanced-stage malignant pheochromocytomas are resistant to conventional therapy, such as radiation therapy and chemotherapy. However, based on three very recent reports, sunitinib appears to be useful for the treatment of malignant pheochromocytomas (15, 25, 26) . Pheochromocytomas often display hypervascularity (5, 14, 27, 35) . Therefore, it is reasonable to speculate that inhibition of angiogenesis could be a rational therapeutic target in these tumors, probably through a logical mechanism of action similar to that in other hypoxiainducible tumors, such as renal cell carcinoma.
However, the antitumor effects of sunitinib in malignant pheochromocytomas have not been clearly established. In particular, it is unclear whether sunitinib acts primarily through only antiangiogenic mechanisms or also directly targets tumor cells. Recent studies revealed that sunitinib markedly reduced plasma catecholamine levels in patients with pheochromocytomas (15, 25, 26) . This inhibitory effect of sunitinib on catecholamine strongly suggests the possibility that sunitinib may have direct inhibitory effects on catecholamine synthesis and secretion. To support this, we recently demonstrated that sunitinib directly induced apoptosis through inhibition of the protein kinase B (Akt)/mammalian target of rapamycin (mTOR)/ ribosomal protein S6 kinase 1 (S6K1) pathway in PC-12 cells. Additionally, it is of note that VEGFR-2 silencing attenuated these sunitinib-induced effects, indicating that sunitinib exerts its effects through VEGFR-2 (36) .
Tyrosine hydroxylase (TH) is a rate-limiting enzyme in the biosynthesis of catecholamine. TH activity is regulated by both short-and long-term mechanisms. Short-term regulation occurs at the posttranslational level. Central to this regulation is the phosphorylation of TH, which results in enzyme activation (4, 8, 10, 16, 17, 45 40 has a major effect on TH activity. In addition to the short-term regulation of TH activity, long-term control occurs at the transcriptional level (6, 20, 29) . Mobilization of Ca 2ϩ in chromaffin cells is important for the induction of catecholamine secretion. One important mechanism for intracellular Ca 2ϩ ([Ca 2ϩ ] i ) regulation is the release of Ca 2ϩ from intracellular storage sites mediated by inositol 1,4,5-trisphosphate (IP 3 ) formation following PLC-␥ activation (12, 18) .
The aim of the present study was to determine whether sunitinib directly inhibits catecholamine synthesis and/or secretion in undifferentiated PC-12 cells, which are a wellestablished experimental model of pheochromocytoma. However, it is known that PC-12 cells do not accurately reflect the pathogenesis of malignant cells. Recently, certain neural crestderived tumors, such as pheochromocytoma and neuroblastoma, were reported to have common genetic background (37, 38) . Therefore, we confirmed the effects of sunitinib in a human neuroblastoma cell line, SK-N-SH. An additional objective of this study was to clarify the mechanisms underlying sunitinib-mediated inhibition of catecholamine synthesis and/or secretion in these cells.
MATERIALS AND METHODS
Reagents. Unless otherwise noted, all reagents were purchased from Wako Pure Chemical Industries (Osaka, Japan). Sunitinib was a gift from Pfizer.
Cell culture. The PC-12 cell line (RCB0009) was obtained from the RIKEN Cell Bank (Ibaraki, Japan). The cells were grown in DMEM (Invitrogen) containing 10% horse serum (Invitrogen) and 10% FBS (Invitrogen) in a humidified atmosphere of 5% CO2 and 95% O2 at 37°C. The human neuroblastoma cell line SK-N-SH (RCB0426) was obtained from the RIKEN Cell Bank. The cells were maintained in minimal essential medium-␣ (Invitrogen) containing 10% FBS.
TH activity. TH activity was measured using the method previously reported (3) . Cells were incubated with either dimethyl sulfoxide (DMSO) (control) or sunitinib at 37°C for 12 h. The cells were then homogenized in 0.25 M sucrose (50 volumes) using a glass tissue grinder. The standard incubation medium consisted of the following components in a total volume of 250 l: 100 l cell homogenate, 40 l of 1 M sodium acetate buffer (pH 6.0), 40 l of 1 mM L-tyrosine or D-tyrosine, 20 l of 1 M 6-methyl-5,6,7,8-tetra-hydropterine in 1 M 2-mercaptoethanol, 20 l of 20 mg/ml catalase, and 30 l water. The medium was incubated at 37°C for 30 min, and the reaction was stopped by addition of 1 M perchloric acid containing dihydroxy benzylamine as an internal standard, and 0.2 M EDTA, and by storage at ice temperature. Next, 1 M potassium carbonate and 0.2 M Tris·HCl (pH 8.5) containing 2% EDTA were added. The 3,4-dihydroxyphenylalanine (DOPA) was extracted using the aluminium oxide method. Two hundred forty microliters of extracted medium were mixed with 0.1 N NaOH and Amberlite CG-50 (MP Biomedicals, Illkirch, France) and analyzed by HPLC. The mobile phase consisted of the following components: 50 mM sodium acetate, 20 mM citric acid, 20 mM sodium octyl sulfate, 1 mM di-n-butylamine, and 0.134 mM EDTA. All separations were performed isocratically at a flow rate of 0.6 ml/min at 29°C. The enzyme activity was calculated as the amount of DOPA formed from tyrosine per milligram protein in 30 min.
Small-interfering RNA transfection. RNA interference was performed as previously described (36) . Briefly, cells were grown in culture medium, and, 24 h later, the cells were transfected with Silencer Select siRNA (Ambion) using RNAiMAX (Invitrogen) according to the manufacturer's instructions. At the same time, nontargeting Silencer Select siRNA (Ambion) was transfected as a negative control. Quantitative real-time PCR was carried out as described previously (36) .
PKC activity. PKC activity was measured as previously described (3). Cells were incubated with either DMSO (control) or sunitinib at 37°C for 12 h. The cells were then harvested, homogenized, and incubated for 30 min with 100 l reaction buffer solution containing a pseudosubstrate and various phospholipids from a commercially available kit (Pep Taq-Non-radioactive PKC activity kit; Promega). The reaction was stopped by heating, and then the reaction mixture was separated into phosphorylated and nonphosphorylated substrates on a 0.9% agarose gel. The band intensities were measured by densitometry.
Determination of catecholamine secretion. The level of catecholamine in medium was determined as follows. Briefly, cells were grown in culture medium, which was then replaced with medium containing either DMSO (control) or sunitinib. Next, the cells were incubated at 37°C for 12 h. An aliquot of incubation medium was analyzed for catecholamine.
Determination of intracellular catecholamine contents. Catecholamine contents in cells were determined as follows. Briefly, cells were treated with either DMSO (control) or sunitinib at 37°C for 12 h. The cells were harvested and homogenized, and then the homogenates were diluted and analyzed for catecholamine. Catecholamine contents were corrected for protein concentration.
Immunoblotting. Immunoblotting was carried out as previously described (23, 36) . Antibody to phospho-specific TH at Ser 40 and Ser 19 /Ser 31 were from New England Biolabs and Calbiochem, respectively. The other antibodies were purchased from Cell Signaling Technology. The band intensities were measured by densitometry.
IP 3 production. Measurement of IP3 production was carried out using the fluorescence polarization detection kit [HitHunter Inositol (1,4,5)-Trisphosphate Assay; DiscoveRx]. Briefly, cells were incubated with either DMSO (control) or sunitinib at 37°C for 12 h. The cells were then harvested and titrated in a 96-well microtiter plate. Assay ran on Infinite F200 PRO (Tecan Group, Mannedorf, Switzerland). In this assay kit, the polarized signal is inversely proportional to the amount of IP 3 in the cell lysate. All assays were according to the manufacturer's instructions.
Statistical analysis. The results are expressed as means Ϯ SE. The significance of differences in the data was determined by an analysis of the paired Student's t-test or Dunnett's test. P values Ͻ0.05 were considered significant. All data were analyzed using the software SPSS version 19.0 (SPSS).
RESULTS

Effect of sunitinib on TH activity in PC-12 cells.
Because TH is the initial and rate-limiting enzyme in catecholamine biosynthesis, we tested the effect of sunitinib on TH activity. Nicotine is known to stimulate catecholamine synthesis in chromaffin cells. Initially, we confirmed that nicotine (10 M) increased TH activity ϳ1.5-fold compared with the basal value in PC-12 cells; thus, this was used as a convenient positive control in this study. As shown in Fig. 1A , sunitinib at 10, 100, and 1,000 nM significantly decreased TH activity to 79, 74, and 68% of the basal value, respectively.
Effect of sunitinib on TH phosphorylation in PC-12 cells. To reinforce the sunitinib-mediated inhibition of TH activity, we also examined the effect of sunitinib on the phosphorylation of TH at Ser 19 , Ser 31 , and Ser 40 , which functions in the short-term regulation of enzyme activity. Sunitinib significantly decreased TH phosphorylation at Ser 31 and Ser 40 in a dose-and timedependent manner (Fig. 2) . In contrast, sunitinib did not affect phosphorylation at Ser 19 (data not shown).
Effect of sunitinib on TH protein levels in PC-12 cells.
We also examined the effect of sunitinib on the long-term regulation of TH activity. Cells were treated with sunitinib (1,000 nM), and TH protein level was examined by immunoblotting. As shown in Fig. 3, sunitinib significantly decreased the level of TH protein, to ϳ60% of the basal value. Cells were incubated for 12 h with either dimethyl sulfoxide (DMSO) (control) or various concentrations of sunitinib (10, 100, and 1,000 nM). In other experiments, cells were transfected with either small-interfering RNA (siRNA) targeting VEGFR-2 or negative control siRNA (siCON), and, 48 h later, the cells were treated with sunitinib (1,000 nM) for 12 h. TH activity was measured as described in MATERIALS AND METHODS. B and C: the sunitinib-mediated inhibition of TH activity is not affected by the silencing of platelet-derived growth factor receptor (PDGFR)-␣, PDGFR-␤, stem cell factor receptor (c-Kit), fms-related tyrosine kinase 3 (Flt-3), or colony-stimulating factor 1 receptor (CSF-1R) in PC-12 cells. Cells were incubated with either DMSO (control) or sunitinib (1,000 nM) for 12 h. In other experiments, cells were transfected with either siCON or siRNA targeting PDGFR-␣, PDGFR-␤, c-Kit, Flt-3, and CSF-1R, and, 48 h later, the cells were treated with sunitinib (1,000 nM) for 12 h. After knockdown, individual mRNA levels were determined by quantitative real-time PCR analysis. TH activity was measured as described in MATERIALS AND METHODS. The data shown represent the means Ϯ SE of 3 independent experiments (1 experiment was performed with 2 samples). *P Ͻ 0.05 vs. the basal value. #P Ͻ 0.05 vs. the value in siCON-transfected cells treated with sunitinib (1,000 nM). Fig. 4A , sunitinib (1,000 nM) significantly inhibited catecholamine secretion to ϳ40% of the basal level. It is known that the intracellular catecholamine level is correlated with catecholamine synthesis. Therefore, to confirm that sunitinib inhibits catecholamine synthesis, we examined the effect of sunitinib on intracellular catecholamine. As shown in Fig. 4C , sunitinib (1,000 nM) significantly reduced intracellular catecholamine to ϳ60% of the basal level.
Effect of sunitinib on catecholamine release and intracellular catecholamine in PC-12 cells. As shown in
Effect of VEGFR-2 knockdown on sunitinib-mediated inhibition of catecholamine synthesis and secretion in PC-12 cells.
To further confirm whether sunitinib exerts its effects through VEGFR-2, we examined the effect of VEGFR-2 knockdown on catecholamine synthesis and secretion. VEGFR-2 knockdown by small-interfering RNA (siRNA) was previously confirmed by immunoblotting (36) . As shown in Figs. 1A, 4A, and 4C, VEGFR-2 silencing attenuated sunitinib-induced effects, such as the reduction of TH activity, catecholamine secretion, and intracellular catecholamine, compared with that of the negative control siRNA. These results indicate that these sunitinib-mediated inhibitory effects could be mediated by VEGFR-2.
It is known that sunitinib exerts its effects via multiple RTKs. Indeed, Manley et al. (30) reported that the half-maximal inhibitory concentration (IC 50 ) values of sunitinib for PDGFR-␣ and PDGFR-␤ are 55 and 35 nM, whereas those for VEGFR-1, -2, and -3 are 15, 38, and 30 nM, respectively. Moreover, sunitinib is also a potent inhibitor of CSF-1R, Flt-3, and c-Kit (IC 50 values of 35, 21, and 10 nM, respectively) (30). Consistent with this notion, multitargeted therapies, such as sunitinib, are likely to have more antitumor activities than those targeting a single pathway. Therefore, we determined whether multiple RTKs, such as PDGFR-␣, PDGFR-␤, c-Kit, Flt-3, and CSF-1R, were involved in sunitinib-mediated inhibition of catecholamine synthesis and secretion. As shown in Fig. 1B , mRNA expression was determined by quantitative real-time PCR, confirming the knockdown of target genes by siRNA. In contrast to what was observed with knockdown of VEGFR-2, knockdown of these other RTKs did not affect the sunitinib-mediated inhibition of either catecholamine synthesis or secretion (Figs. 1C and 4B) .
Effect of sunitinib on PLC-␥ and PKC in PC-12 cells.
It is known that VEGFR-2 utilizes the PLC-␥/PKC/Raf/MEK/ERK pathway (40, 41) . To clarify the mechanisms underlying sunitinibmediated inhibition of TH activity, we examined the effect of sunitinib on PLC-␥ phosphorylation. As shown in Fig. 5A , sunitinib at 100 and 1,000 nM significantly decreased PLC-␥ phosphorylation to ϳ50% of the basal value. Phosphorylation of TH at Ser 40 has a major effect on activity and is known to be regulated by PKC. Combining these findings with the inhibition of TH activity and Ser 40 phosphorylation by sunitinib, we examined the effect of sunitinib on PKC activity. As shown in Fig.  5B , sunitinib at 100 and 1,000 nM significantly decreased PKC activity to ϳ70 and 60% of the basal value, respectively. Therefore, sunitinib may inhibit TH phosphorylation at Ser 40 via inhibition of the VEGFR-2/PLC-␥/PKC pathway.
Effect of sunitinib on mitogen-activated protein kinase activity in PC-12 cells. Mitogen-activated protein kinases (MAPK) pathways are known to be among the most significant cellular signaling sequences (11) . Therefore, we determined whether sunitinib affects the activity of MAPKs, including p44 and p42 MAPK (ERK), p46 and p54 c-Jun NH 2 -terminal kinase, and p38 MAPK (p38-␣, -␤, -␥, and -␦), in PC-12 cells. When cells were treated with sunitinib for 12 h, ERK phosphorylation decreased significantly with 100 nM sunitinib, and was ϳ50% at 1,000 nM (Fig.  6A) . Inhibition was evident 12 h after onset of treatment and lasted for at least 48 h (at ϳ50% of the basal value) (Fig. 6B) . In contrast to the sunitinib-mediated inhibition of ERK phosphorylation, sunitinib did not affect the other MAPKs tested (data not shown).
Effect of sunitinib on IP 3 production in PC-12 cells. Because sunitinib was shown to inhibit PLC-␥ phosphorylation (Fig.  5A) , we tested whether sunitinib inhibited the production of Fig. 3 . Effect of sunitinib on TH protein level in PC-12 cells. Cells were incubated with sunitinib (1,000 nM) for the indicated times, and then TH protein was measured by immunoblotting as described in MATERIALS AND METHODS. Representative data are shown, and these data were reproducible in 3 independent experiments. The value in the histogram represents the mean Ϯ SE of the densitometric measurements of the indicated parameter. Under basal conditions, this ratio was set to 100%. *P Ͻ 0.05 vs. the basal value. Fig. 4 . A: sunitinib inhibits catecholamine secretion, and this inhibition is abolished by VEGFR-2 silencing in PC-12 cells. Cells were treated with either DMSO (control) or sunitinib (1,000 nM) for 12 h. In other experiments, cells were transfected with either siVEGFR-2 or siCON, and, 48 h later, the cells were treated with sunitinib (1,000 nM) for 12 h. The media were examined as described in MATERIALS AND METHODS. B: the sunitinib-mediated inhibition of catecholamine secretion is not affected by the silencing of PDGFR-␣, PDGFR-␤, c-Kit, Flt-3, or CSF-1R in PC-12 cells. Cells were treated with either DMSO (control) or sunitinib (1,000 nM) for 12 h. In other experiments, cells were transfected with either siCON or siRNA targeting PDGFR-␣, PDGFR-␤, c-Kit, Flt-3, and CSF-1R, and, 48 h later, the cells were treated with sunitinib (1,000 nM) for 12 h. The medium were examined as described in MATERIALS AND METHODS. C: sunitinib inhibits intracellular catecholamine content, and this inhibition was abolished by VEGFR-2 silencing in PC-12 cells. Cells were treated with either DMSO (control) or sunitinib (1,000 nM) for 12 h. In other experiments, cells were transfected with either siVEGFR-2 or siCON, and, 48 h later, the cells were treated with sunitinib (1,000 nM) for 12 h. Cell lysates were examined as described in MATERIALS AND METHODS. The values shown represent the means Ϯ SE (n ϭ 4 -6). Because the major catecholamine synthesized in PC-12 cells is dopamine, and the production of norepinephrine and epinephrine was negligible, dopamine levels are presented. *P Ͻ 0.05 vs. the basal value. #P Ͻ 0.05 vs. the value in siCON-transfected cells treated with sunitinib (1,000 nM). IP 3 , a messenger for the mobilization of Ca 2ϩ from intracellular storage sites. As shown in Fig. 7 , sunitinib at 100 and 1,000 nM significantly increased the polarized signal, representing the reduction of IP 3 production in cells.
Effect of sunitinib on TH activity in a human neuroblastoma cell line. To confirm the key findings of this study, we examined the effect of sunitinib on TH activity in a human neuroblastoma cell line, SK-N-SH (37, 38) . Similar to what was observed in PC-12 cells, TH activity in SK-N-SH cells decreased significantly, to ϳ60% of the basal value (Fig. 8) . In addition, this inhibition was abolished by VEGFR-2 silencing in SK-N-SH cells.
DISCUSSION
In this study, we demonstrated that sunitinib directly inhibits catecholamine synthesis and secretion in pheochromocytoma PC-12 cells, indicating that the sunitinib-mediated inhibition of catecholamine secretion observed in a previous paper may be explained, at least in part, through the direct inhibition of tumor cells rather than the inhibition of angiogenesis. Indeed, we demonstrated that sunitinib (10 nM) significantly decreased TH activity (Fig. 1A) . Because sunitinib exhibits a similar inhibi- Fig. 5 . Sunitinib inhibits phospholipase C (PLC)-␥ phosphorylation and protein kinase C (PKC) activity in PC-12 cells. Cells were treated with either DMSO (control) or various concentrations of sunitinib (10, 100, and 1,000 nM) for 12 h. Cell lysates were subjected to SDS-PAGE and immunoblotted with anti-phospho-specific PLC-␥ (Try 783 ) or anti-PLC-␥ antibody (A). PKC activity was assayed as described in MATERIALS AND METHODS (B). Representative data are shown, and these data were reproducible in 3 independent experiments. The value in the histogram represents the mean Ϯ SE of the densitometric measurements of the indicated parameter. Under basal conditions, this ratio was set to 100%. *P Ͻ 0.05 vs. the basal value. Fig. 6 . Effect of sunitinib on extracellular signal-regulated kinase (ERK) activity in PC-12 cells. Cells were treated with sunitinib at the indicated concentrations for 12 h (A) or at 1,000 nM for the indicated times (B). Cell lysates were subjected to SDS-PAGE and immunoblotted with anti-phosphop44 and p42 mitogen-activated protein kinase (MAPK) antibody or anti-p44 and p42 MAPK antibody. Details are described in MATERIALS AND METHODS. Representative data are shown, and these data were reproducible in 3 independent experiments. The value in the histogram represents the mean Ϯ SE of the densitometric measurements of the indicated parameter. Under basal conditions, this ratio was set to 100%. *P Ͻ 0.05 vs. the basal value. Fig. 7 . Effect of sunitinib on inositol 1,4,5-trisphosphate (IP3) production in PC-12 cells. Cells were treated with sunitinib at the indicated concentrations for 12 h, and IP3 levels were measured as described in MATERIALS AND METHODS. The polarized signal is inversely proportional to the amount of IP3. The data shown represent the mean Ϯ SE of 3 independent experiments (1 experiment was performed with 2 samples). *P Ͻ 0.05 vs. the basal value. tory potency (inhibitory constant ϭ 0.009 M) on VEGFR-2 in biochemical assays (13), we speculate that sunitinib could inhibit VEGFR activation at the above concentrations.
Consistent with this finding, sunitinib reduced TH phosphorylation at two sites, Ser 31 and Ser 40 , known to correlate with TH activity (Fig. 2) . Specifically, sunitinib at 1,000 nM significantly decreased TH protein (Fig. 3) . Therefore, it is likely that sunitinib directly reduces TH activity by controlling shortand long-term regulation in PC-12 cells. In agreement with the reduction in TH activity, intracellular catecholamine was significantly decreased (Fig. 4C) .
To further confirm that VEGFR-2 was involved in sunitinibmediated inhibition, we silenced VEGFR-2 with siRNA. Indeed, VEGFR-2 knockdown attenuated the sunitinib-induced effects, including the reduction of TH activity, catecholamine secretion, and intracellular catecholamine, confirming that these sunitinib-induced effects could be mediated by VEGFR-2 (Figs. 1A, 4A , and 4C). It is known that sunitinib exerts its effects via multiple RTKs (30) . To exclude the possibility that other RTKs were involved in the sunitinib-induced effects we observed, we knocked down multiple RTKs, such as PDGFR-␣, PDGFR-␤, c-Kit, Flt-3, and CSF-1R (Fig. 1B) . However, silencing of other RTKs did not affect the inhibitory effect of sunitinib on either catecholamine synthesis or secretion (Figs.  1C and 4B ). Although we did not examine all of the RTKs reported, our results support the idea that the inhibitory effects obtained were mainly due to inhibition of VEGFR-2 and not due to the inhibition of the other RTKs, in agreement with the fact that silencing of VEGFR-2 alone markedly attenuated the sunitinib-induced effects.
To reinforce these findings, sunitinib significantly decreased PLC-␥ phosphorylation and PKC activity in PC-12 cells (Fig.  5) . Because TH phosphorylation at Ser 40 is positively regulated by PKC, it is reasonable to speculate that sunitinib inhibits TH phosphorylation at Ser 40 thorough the inhibition of VEGFR-2, followed by the PLC-␥/PKC pathway, thus resulting in a significant reduction of TH activity in PC-12 cells.
The physiological relevance of TH phosphorylation at Ser 31 is unclear. However, it was reported that at Ser 31 phosphorylation might be required for full TH activation (7). In our experimental system, we demonstrated that sunitinib decreased ERK phosphorylation (Fig. 6) . Although the physiological relevance of the differences between MAPKs observed in the present study remains unclear, it suggests that sunitinib may reduce TH phosphorylation at Ser 31 through inhibition of the VEGFR-2/PLC-␥/PKC/Raf/MEK/ERK pathway.
Another important point made in this study was that sunitinib inhibited catecholamine secretion from PC-12 cells. Additionally, we demonstrated that sunitinib significantly inhibited IP 3 production (Fig. 7) . It is well established that [Ca 2ϩ ] i is regulated by Ca 2ϩ release from intracellular storage sites mediated by IP 3 formation following PLC-␥ activation (12) . Therefore, we can suggest that sunitinib inhibits PLC-␥ phosphorylation and leads to reduced IP 3 production, which mediates [Ca 2ϩ ] i , and is consistent with the notion that sunitinib directly inhibits catecholamine secretion. The precise relationship between VEGFR-2 and Ca 2ϩ mobilization remains obscure. However, it has been previously shown that PLC-␥ activation via VEGFR stimulation, followed by IP 3 production and increased PKC activity, leads to increased [Ca 2ϩ ] i in primary endothelial cells (31) . The pathophysiological role of RTKs, including VEGFR, in regulating catecholamine secretion in chromaffin cells also remains uncertain (28) . Further studies are needed to clarify these points.
It is known that pheochromocytoma PC-12 cells, which are well established and extensively used, do not accurately reflect the pathogenesis of malignant tumor cells. Pheochromocytomas and neuroblastomas are derived from the sympathetic nervous system. Despite their embryologic relationship, a review of the literature suggests the lack of an association Fig. 9 . Proposed model for the direct effects of sunitinib on TH activity and catecholamine secretion in PC-12 cells. Results suggested by the current experiments together with data form the basis of our previous report (36) . Sunitinib inhibits components of VEGFR-2-mediated signaling, such as PLC-␥ and the PKC/Raf/ERK pathway. TH activity is known to be regulated by phosphorylation at Ser 31 and Ser 40 , and phosphorylation at these sites is inhibited by sunitinib-mediated inhibition of ERK and PKC activity, respectively. In addition, decreased catecholamine secretion is dependent on the mechanisms by which sunitinib inhibits Ca 2ϩ release from intracellular storage sites through IP3 formation, which follows PLC-␥ inactivation. Furthermore, sunitinib initially exerts its apoptotic effect through VEGFR-2 inhibition, which when followed by reduction of its downstream effectors, including protein kinase B (Akt)/mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase 1 (S6K1), may lead to inhibition of the antiapoptotic molecule Bcl-2 and activation of the proapoptotic molecule Bad in PC-12 cells. Fig. 8 . Sunitinib inhibits TH activity, and this inhibition is abolished by VEGFR-2 silencing in a human neuroblastoma cell line. SK-N-SH cells were incubated for 12 h with either DMSO (control) or sunitinib (1,000 nM). In other experiments, SK-N-SH cells were transfected with either siVEGFR-2 or siCON, and, 48 h later, the cells were treated with sunitinib (1,000 nM) for 12 h. TH activity was measured as described in MATERIALS AND METHODS. The data shown represent the means Ϯ SE of 3 independent experiments (1 experiment was performed with 2 samples). *P Ͻ 0.05 vs. the basal value. #P Ͻ 0.05 vs. the value in siCON-transfected cells treated with sunitinib (1,000 nM).
between them. However, regarding the molecular pathogenesis, these neural crest-derived tumors reportedly share a common genetic background, such as SDHB and KIF1B␤ (37, 38) . Therefore, we confirmed that sunitinib exerted the same effects on catecholamine synthesis in a human neuroblastoma cell line (Fig. 8) .
In the clinical setting, sunitinib is reported to significantly inhibit catecholamine secretion (15, 25, 26) . This, along with our present findings, suggests that sunitinib directly inhibits catecholamine synthesis and secretion during treatment of malignant pheochromocytomas. In addition, it is of note that TH is strongly activated in pheochromocytomas compared with normal adrenal medullas (24) . Therefore, inhibition of TH activity by sunitinib seems to be the rationale for treatment of malignant pheochromocytomas.
Growing evidence suggests that the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR/S6K1 pathways may play an important role in the pathogenesis of pheochromocytomas. TMEM127, a new tumor suppressor gene reported to be associated with pheochromocytoma development, encodes a protein that suppresses mTOR activation. Indeed, the authors found that S6K1 phosphorylation increased in TMEM127 mutant pheochromocytomas compared with normal adrenal medullas (34, 42, 44) . Therefore, activation of the PI3K/Akt/ mTOR/S6K1 pathways may also be involved in the pathogenesis of pheochromocytomas.
We recently demonstrated that sunitinib directly induces apoptosis in PC-12 cells by inhibiting the VEGFR-2/Akt/ mTOR/S6K1 pathways through modulation of Bcl-2 and Bad (36) . Based on this finding along with our present results, it would appear that sunitinib exerts its antitumor effects, at least in part, through direct inhibition of catecholamine synthesis and secretion as well as apoptosis rather than by inhibiting angiogenesis (Fig. 9) .
